Ludzkie koronawirusy - autor: Krzysztof Pyrć z Zakładu Mikrobiologii, Wydział Biochemii, Biofizyki i Biotechnologii, Uniwersytet Jagielloński, Kraków

Zastanawiasz się, jak wydać pracę doktorską, habilitacyjną lub monografię? Chcesz dokonać zmian w stylistyce i interpunkcji tekstu naukowego? Nic prostszego! Zaufaj Wydawnictwu Borgis – wydawcy renomowanych książek i czasopism medycznych. Zapewniamy przede wszystkim profesjonalne wsparcie w przygotowaniu pracy, opracowanie dokumentacji oraz druk pracy doktorskiej, magisterskiej, habilitacyjnej. Dzięki nam nie będziesz musiał zajmować się projektowaniem okładki oraz typografią książki.

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - New Medicine 2/2011, s. 72-75
*Zsolt Petke1, Judit Mészáros2, István Vingender2, Zsolt Demetrovics3, Judit Farkas3, Zsuzsanna Kovács4, Zsuzsa Menczel4, Anna Havasi2, Péter Simor5, József Rácz1,6
Early dropout after one month of buprenorphine/naloxone maintenance therapy
1Department of Addictology, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary
2Faculty of Health Sciences, Semmelweis University, Budapest, Hungary
3Eötvös Lóránd University, Institutional Group on Addicition Research, Budapest, Hungary
4Department of Applied Psychology, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary
5University of Technology and Economics, Department of Cognitive Sciences, Budapest, Hungary
6Institute for Psychology, Hungarian Academy of Sciences, Budapest, Hungary
Introduction. Suboxone (Buprenorphine/naloxone) is a drug used in opiate substitution therapy. In Hungary, it was introduced in November 2007. Suboxone is a product for sublingual administration containing the partial p-receptor agonist buprenorphine and antagonist naloxone in a 4:1 ratio.
Aim. Objectives of our study were to monitor and evaluate the psychosocial changes after one month of Suboxone treatment.
Material and methods. 6 outpatient centres participated in the study; 3 from Budapest and 3 from smaller cities in Hungary. At these centres, all patients entering Suboxone maintenance therapy between November 2007 and March 2008, totalling 80 persons (55 males, 35 females, mean age = 30,2 years, SD=5,48) were included in the study sample. During the 6-month period of treatment, data were collected 4 times; when entering treatment, 1 month, 3 months, and 6 months after entering treatment. Applied measure was the Addiction Severity Index.
Results. Nearly fourth of the total of 80 heroin dependent patients (18 persons, 22.5%) dropped out of treatment during the first month (the majority, 12 persons [15%] during the first week) or chose methadone substitution instead. During the first month of treatment significant positive changes were observed in all studied psychological and behavioural dimensions and proved to be stable throughout the studied period.
Conclusions. According to the experience with Suboxone treatment, it is a well tolerable and successfully applicable drug in the substitution therapy of opiate addicts. A critical phase seems to be the first one or two weeks of treatment. Dropout rate is high during this early period, whereas after a successful conversion patients presumably remain in therapy for a long period. At the beginning of administration special emphasis must be put on informing patients, especially concerning withdrawal symptoms that might be present during the first week, which highly contributes to better retention in treatment.
Out of all drug patients entering treatment in Hungary in 2008, 17% used opiates, typically injected heroin (Hungarian National Focal Point, 2009). The aim of agonist maintenance treatments is to reduce public health risks related to intravenous heroin use; infections (mainly HIV and hepatitis C), criminality, overdose, and to increase life quality, physical and mental health of patients (World Health Organization, 2009). Besides the widespread methadone maintenance treatment in Hungary (677 patients received such treatment in 2008; Hungarian National Focal Point, 2009), in 2007 the need arose for the introduction of a sublingual product (Suboxone) containing buprenorphine and naloxone in a 4:1 ratio. The reasons were its clinical advantages compared to methadone due to its favourable characteristics when applied in treatment; less euphoric and sedative effects, good tolerability, no unwanted side effects (overdose) (Amass et al., 2004; Kakko et al., 2007; Kleber, 2007; Orman & Keating, 2009a, 2009b), and the fact that intravenous heroin use significantly decreases during the maintenance treatment (Mammen & Bell, 2009). Suboxone, besides its application in substitution maintenance programs, is effectively adaptable in the preparation of patients for abstinence-oriented programs, hence effectively applicable for the aim of detoxification as well (Amass et al., 2004; Johnson & McCagh, 2000; Van den Brink & Haasen, 2006)
At the same time, there are only a few studies on the efficacy of Suboxone treatment even in the international scope. Objectives of our study were monitoring and evaluating the effect of Suboxone treatment parallel with the introduction of the product in Hungary. Besides exploring dropout ratio and the dimensions influencing it, we also intended to study the changes occurring in the course of treatment.
All opiate dependent patients entering Suboxone maintenance treatment therapy between November 2007 and March 2008 in Hungary were included in the study sample. Suboxone therapy was provided at six treatment centres during this period:
1. Nyírő Gyula Hospital Drug Outpatient and Prevention Centre, Budapest
2. Soroksár Addiction Treatment Centre, Budapest
3. Blue Point Drug Counseling and Outpatient Centre, Budapest
4. INDIT Foundation Baranya County Drug Outpatient Centre, Pécs
5. BMKT Pándy K. Hospital, Drug Outpatient Centre, Gyula
6. Dr. Farkasinszky Terézia Drug Outpatient Centre, Szeged
During the study period 80 opiate dependent patients were involved in Suboxone treatment. Before entering the treatment, all patients received detailed information on Suboxone therapy. 68.8% (55 persons) of the study sample were male, while 31.2% (25 persons) were female. Mean age was 30.2 years (sd=5.48 years, with an age range of 18-45 years).
Treatment protocol
The treatment was carried out according to the guidelines of the Suboxone Therapy Protocol. The appropriate dose and dosage was defined by the doctors responsible for the treatment, these parameters were not influenced by the present study. The applied dosage was between 6 and 32 mg (mean dose: 19.3 mg; SD=5.3 mg) however, most of the patients (87.5%) received 16-24 mg buprenorphine per day. During the first 30 days of treatment patients were obliged to attend the treatment centres daily. For two weeks after the first month visit on every second or third day, and after this period period weekly visits were required.
During the study, besides the necessary laboratory examinations, HIV and HCV tests, we have assessed the severity of addiction, prevalence of comorbid psychiatric disorders and other parameters regarding the patients’ psychosocial status.
Addiction severity
Extent of dependence was measured with the Addiction Severity Index (ASI). Hungarian experiences with the measure of McLellan and colleagues (McLellan et al., 1992) show satisfactory results concerning validity and reliability of the applied measure (Gerevich, Bacskai, Ko, & Rozsa, 2005; Rácz, Pogány, & Máthé- Árvay, 2002).
The extent of craving was assessed by the Heroin Craving Questionnaire of Tiffany et al. (Schuster, Greenwald, Johanson, & Heishman, 1995; Tiffany, Fields, Singleton, Haertzen, & Henningfield, 1995). The scale consists of fives subscales; (1) Desire to Use Heroin; (2) Intentions and Plans to Use Heroin; (3) Anticipation of Positive Outcome; (4) Relief from Withdrawal or Dysphoria; (5) Lack of Control over Use. Reliability indices of the scale are satisfactory (Cronbach’s a for the entire scale is .962; while for the subscales: .907; .892; .857; 782; and .815 respectively).
The short version of the WHO well-being questionnaire was applied (Bech, Gudex, & Johansen, 1996; Susánszky, Konkoly Thege, Stauder, & Kopp, 2006). Reliability of the scale is satisfactory (Cronbach’s a=0.782).
Changes in the measured dimensions during treatment were studied in a prospective design.
In the first month of treatment, data on patients were collected 2 times; right before entering treatment (T0) and 1 month after(Tj). Patients entering Suboxone maintenance treatment therapy between November 2007 and March 2008 became part of the study sample. Regarding the 6-month follow-up period, data collection ended on 30th October, 2008.
In the study period 80 opiate dependent persons entered Suboxone therapy in one of the six treatment centres. 18 persons (22.5%) dropped out of treatment within one month. Highest dropout rate was present in the first week; 12 persons (15%) left the treatment during this period.
Changes in the specific dimensions were analyzed by means of paired sample t-tests, by comparing the mean values of consecutive points of data collection. In all seven profiles of ASI a favourable transition could be observed after the first month of treatment. There was a significant improvement in all assessed dimensions during the first month of treatment (p<0.001)
Similarly, there was a significant improvement in the well-being dimension during the first month and no further changes occurred in the following months.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.

Płatny dostęp do wszystkich zasobów Czytelni Medycznej

Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu oraz WSZYSTKICH około 7000 artykułów Czytelni, należy wprowadzić kod:

Kod (cena 30 zł za 30 dni dostępu) mogą Państwo uzyskać, przechodząc na tę stronę.
Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.

1. Amass L, Ling W, Freese TE et al.: Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004; 13 Suppl 1, S42-66. 2. Bech P, Gudex C, Johansen K S: The WHO (Ten) Well-Being Index: validation in diabetes. Psychother Psychosom 1996; 65(4), 183-190. 3. Crévecoeur-MacPhail D, Ransom L, Myers AC et al.: Inside the black box: measuring addiction treatment services and their relation to outcomes. J Psychoactive Drugs 2010; Suppl 6: 269-76. 4. Gerevich J, Bacskai E, Ko J, Rozsa S: Reliability and validity of the Hungarian version of the European Addiction Severity Index. Psychopathology 2005; 38(6): 301-309. 5. Grenard JL, Ames SL, Pentz MA, Sussman S: Motivational interviewing with adolescents and young adults for drug-related problems. Int J Adolesc Med Health. Jan-Mar 2006; 18(1): 53-67. 6. Guydish J, Jessup M, Tajima B, Manser ST: Adoption of motivational interviewing and motivational enhancement therapy following clinical trials. J Psychoactive Drugs 2010; Suppl 6: 215-26. 7. Hettema J, Steele J, Miller WR: Motivational interviewing. Annu Rev Clin Psychol 2005; 1: 91-111. 8. Hungarian National Focal Point: 2009 National Report to the EMCDDA by the Reitox National Focal Point. “Hungary” New developments, trends and in-depth information on selected issues. Budapest: Hungarian National Focal Point 2009. 9. Johnson RE, McCagh JC: Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep 2000; 2(6), 519-526. 10. Kakko J, Gronbladh L, Svanborg KD et al.: A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized mcontrolled trial. Am J Psychiatry 2007; 164(5): 797-803. 11. Kleber HD: Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007; 9(4), 455-470. 12. Magill M, Mastroleo NR, Apodaca TR et al.: Motivational interviewing with significant other participation: assessing therapeutic alliance and patient satisfaction and engagement. J Subst Abuse Treat 2010; 39(4): 391-8. 13. Mammen K, Bell J: The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother 2009; 10(15), 2537-2544. 14. McKay JR: Continuing care research: what we have learned and where we are going. J Subst Abuse Treat. Mar 2009; 36(2): 131-45. 15. McLellan AT, Kushner H, Metzger D et al.: The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9(3), 199-213. 16. Orman JS, Keating GM: Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009; 69(5): 577-607. 17. Orman JS, Keating GM: Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. CNS Drugs 2009; 23(10): 899-902. 18. Rácz J, Pogány C, Máthé-Árvay N: Az EuropASI (Addikció Súlyossági Index) magyar nyelvű változatának reliabilitás- és validitásvizsgálata. Magyar Pszichológiai Szemle 2002; 57(4), 587-603. 19. Schuster C R, Greenwald MK, Johanson CE, Heishman SJ: Measurement of drug craving during naloxone-precipitated withdrawal in methadone-maintained volunteers. Exp Clin Psychopharmacol 1995; 3(4), 424-431. 20. Susánszky É, Konkoly Thege B, Stauder A, Kopp M: A who Jól-lét kérdőív rövidített (WBI-5) magyar változatának validálása a Hungarostudy 2002 országos lakossági egészségfelmérés alapján. Mentálhigiéné és Pszichoszomatika 2006; 7(3): 247-255. 21. Tiffany ST, Fields L, Singleton E et al.: The development of a heroin craving questionnaire. Unpublished manuscript, 1995. 22. Van den Brink W, Haasen C: Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry 2006; 51(10): 635-646. 23. Vigezzi P, Guglielmino L, Marzorati P et al.: Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. J Subst Abuse Treat 2006; 31(1): 3-7. Review. 24. Walker R: Retention in treatment-indicator or illusion: an essay. Subst Use Misuse 2009; 44(1): 18-27. Review. 25. Whitley S D, Kunins HV, Arnsten J H, Gourevitch MN: Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services. J Subst Abuse Treat 2007; 33(1): 85-90. 26. World Health Organization: Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization 2009.
otrzymano: 2011-04-05
zaakceptowano do druku: 2011-05-18

Adres do korespondencji:
*Zsolt Petke
Semmelweis University, Faculty of Health Sciences Department of Addiction Medicine
1085 Budapest, Vas u. 17.
tel.: +36 (1) 4865820; fax: 4865812

New Medicine 2/2011
Strona internetowa czasopisma New Medicine